Malaria remains a persistent health concern, even for countries like Malaysia that achieved zero indigenous cases for several consecutive years. In 2023, a resurgence of cases served as a stark reminder that ongoing surveillance and accurate diagnosis are essential to sustain malaria control efforts. In this context, Medical Innovation Ventures Sdn. Bhd. (Mediven) has emerged as a pioneer in advanced malaria diagnostics with its GenoAmp® Real-Time PCR Malaria Kit.
Unlike conventional microscopy, Mediven’s PCR-based solution offers precise identification of all five major Plasmodium species that infect humans:
- P. falciparum
- P. vivax
- P. ovale
- P. malariae
- P. knowlesi
Critically, Mediven was among the earliest companies to develop a commercial PCR kit capable of detecting Plasmodium knowlesi, a zoonotic malaria species increasingly reported in Southeast Asia and frequently misdiagnosed due to its similarity to P. malariae under a microscope.
The GenoAmp® Real-Time PCR Malaria Kit uses real-time multiplex PCR technology to deliver:
- High sensitivity and specificity, clinically validated
- Rapid turnaround time—results in just 1 hour and 9 minutes
- No sample pooling needed—ideal for both small and high-throughput settings
- Ready-to-use reagents, reducing hands-on time
- Flexible compatibility with common extraction systems and PCR instruments
These features streamline malaria diagnosis, eliminate species misidentification, and help clinicians choose the most appropriate treatment especially vital in regions where multiple Plasmodium species are co-endemic.
